New regulatory decisions, manufacturing partnerships, and financing pressures are reshaping access, supply, and development pathways for emerging advanced therapies.
|Articles|March 3, 2010
AstraZeneca Cuts 500 Jobs at US Headquarters
Author(s)Chitra Sethi
AstraZeneca will cut 500 research and development positions at its US headquarters in Fairfax, DE.
Advertisement
London-based pharmaceutical company AstraZeneca will cut 500 research and development positions at its US headquarters in Fairfax, DE. Two facilities in the UK and a research site in Sweden will also be closed as AstraZeneca moves forward with its reorganization plans announced at the beginning of this year.
In January, AstraZeneca had announced its plans to slash 8,000 jobs, or 12% of its work force, by 2014, to cut costs. AstraZeneca’s revenues in 2010 are expected to come under pressure as its key products, child asthma medication Pulmicort and breast cancer treatment Arimidex, lose patent protection.
Advertisement
Related to this article
Caribou is halting vispa-cel and CB-011, allogeneic CAR-T therapies that showed up to 92% response rates, citing a difficult financing environment.
Celltrion USA's Omlyclo, the first interchangeable biosimilar to Xolair, reaches the U.S. market across four allergic and inflammatory indications.
Alvotech turns to a CDMO's 40,000-liter Syracuse facility for biosimilar drug substance as it expands its manufacturing network.
AbbVie's c-Met ADC Temab-A showed a 15.6% response rate in late-line colorectal cancer ahead of its 2 new FDA breakthrough designations.
New data and partnerships are advancing brain-penetrant enzyme therapy, targeted antibodies, flexible obesity dosing, and frontline lymphoma treatment strategies.
Topline phase 3 data show epcoritamab plus R-CHOP reduced the risk of progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma.
Part 2 of the VK2735 maintenance study tests whether daily or weekly oral tablets can hold weight loss first achieved with weekly subcutaneous injections.
Advertisement
Advertisement